SERUM PROTEOMIC PREDICTION OF OUTCOMES IN ADVANCED NSCLC PATIENTS TREATED WITH ERLOTINIB/PLACEBO IN THE NCIC CLINICAL TRIALS GROUP BR.21 TRIAL

被引：0
|
作者：
Carbone, D. P. [1 ]
Seymour, L. [2 ]
Ding, K. [3 ]
Roder, H. [4 ]
Tsao, M. [5 ]
Shepherd, F. A. [5 ]
机构：
[1] Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN USA
[2] Queens Univ, Ncic Ctg, Toronto, ON, Canada
[3] Queens Univ, Commun Hlth & Epidemiol, Kingston, ON K7L 3N6, Canada
[4] Biodesix Inc, Broomfield, CO USA
[5] Princess Margaret Hosp, Toronto, ON, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S80 / S80
页数：1
相关论文
共 50 条
  • [1] Baseline TGF-α and amphiregulin levels in non small cell lung cancer (NSCLC) patients treated with erlotinib or placebo in the NCIC Clinical Trials Group (NCIC CTG) BR.21 clinical trial
    Bradbury, Penelope A.
    Addison, Christina L.
    Goss, Glenwood
    Shepherd, Frances A.
    Seymour, Lesley
    Le Maitre, Aurelie
    Ding, Keyue
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S537 - S538
  • [2] Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial
    Carbone, David P.
    Ding, Keyue
    Roder, Heinrich
    Grigorieva, Julia
    Roder, Joanna
    Tsao, Ming-Sound
    Seymour, Lesley
    Shepherd, Frances A.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : 1653 - 1660
  • [3] A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada clinical trials group study BR.21
    Florescu, Marie
    Hasan, Baktiar
    Seymour, Lesley
    Ding, Keyue
    Shepherd, Frances A.
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) : 590 - 598
  • [4] National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial BR.21. A placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC)
    Ciuleanu, T. E.
    Shepherd, F.
    Pereira, J.
    Tan, E. H.
    Hirsch, V.
    Thongprasert, S.
    Bezjak, A.
    Ding, K.
    Ptaszynski, M.
    Seymour, L.
    ANNALS OF ONCOLOGY, 2004, 15 : 14 - 14
  • [5] Comparison of e-cadherin IHC status with clinical outcomes from erlotinib in the non-small cell lung cancer (NSCLC) clinical trial NCIC CTG BR.21
    Richardson, Frank
    Young, David
    Wolf, Julie
    Sennello, Gina
    Wacker, Bret
    Davies, Angela
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S504 - S505
  • [6] Plasma Transforming Growth Factor α and Amphiregulin Protein Levels in NCIC Clinical Trials Group BR.21
    Addison, Christina L.
    Ding, Keyue
    Zhao, Huijun
    Le Maitre, Aurelie
    Goss, Glenwood D.
    Seymour, Lesley
    Tsao, Ming-Sound
    Shepherd, Frances A.
    Bradbury, Penelope A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (36) : 5247 - 5256
  • [7] Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group study BR.21
    Bezjak, Andrea
    Tu, Dongsheng
    Seymour, Lesley
    Clark, Gary
    Trajkovic, Aleksandra
    Zukin, Mauro
    Ayoub, Joseph
    Lago, Sergio
    de Albuquerque Ribeiro, Ronaldo
    Gerogianni, Alexandra
    Cyjon, Arnold
    Noble, Jonathan
    Laberge, Francis
    Chan, Raymond Tsz-Tong
    Fenton, David
    von Pawel, Joachim
    Reck, Martin
    Shepherd, Frances A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) : 3831 - 3837
  • [8] BRM PROMOTER VARIANTS AND SURVIVAL OUTCOMES OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS: A VALIDATION STUDY IN THE NCIC CLINICAL TRIALS GROUP (NCIC-CTG) BR24 CLINICAL TRIAL
    Cuffe, Sinead
    Cheng, Lu
    Azad, Abul K.
    Brhane, Yonathan
    Cheng, Dangxiao
    Chen, Zhuo
    Qiu, Xin
    Boyd, Kevin
    Leighl, Natasha
    Xu, Wei
    Chen, Bingshu E.
    Bradbury, Penelope
    Shepherd, Frances A.
    Seymour, Lesley
    Tsao, Ming S.
    Reisman, David N.
    Liu, Geoffrey
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S132 - S133
  • [9] Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21
    Zhu, Chang-Qi
    Santos, Gilda da Cunha
    Ding, Keyue
    Sakurada, Akira
    Cutz, Jean-Claude
    Liu, Ni
    Zhang, Tong
    Marrano, Paula
    Whitehead, Marlo
    Squire, Jeremy A.
    Kamel-Reid, Suzanne
    Seymour, Lesley
    Shepherd, Frances A.
    Tsao, Ming-Sound
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (26) : 4268 - 4275
  • [10] EGFR and ABCG2 polymorphisms as prognostic and predictive markers in the NCIC CTG BR.21 trial of single-agent erlotinib in advanced non-small cell lung cancer (NSCLC)
    Liu, G.
    Cheng, D.
    Le Maitre, A.
    Liu, N.
    Chen, Z.
    Seymour, L.
    Ding, K.
    Shepherd, F. A.
    Tsao, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345